Jacobs Levy Equity Management, Inc Travere Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,590,377 shares of TVTX stock, worth $28.7 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
1,590,377
Previous 1,889,844
15.85%
Holding current value
$28.7 Million
Previous $15.5 Million
43.23%
% of portfolio
0.09%
Previous 0.07%
Shares
16 transactions
Others Institutions Holding TVTX
# of Institutions
194Shares Held
83.7MCall Options Held
776KPut Options Held
900K-
Armistice Capital, LLC New York, NY7.65MShares$138 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$138 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$125 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$84.6 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$78.4 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.16B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...